Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Bromberg

Showing results (121-130 of 124) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 124 results.
Journal of Medicinal Chemistry|September 16, 2024
Discovery of A-910, a Highly Potent and Orally Bioavailable Dual MerTK/Axl-Selective Tyrosine Kinase InhibitorYiyun Yu, Miyeon Jang, Julie Miyashiro, et al.
Nature|September 28, 2017
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumoursLoren M Lasko, Clarissa G Jakob, Rohinton P Edalji, et al.
Nature|May 18, 2018
Author Correction: Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumoursLoren M Lasko, Clarissa G Jakob, Rohinton P Edalji, et al.
Molecular Cell|May 21, 2021
Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibitionSimon J Hogg, Olga Motorna, Leonie A Cluse, et al.
Pageof 13

Showing results (121-130 of 124) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 124 results.
Journal of Medicinal Chemistry|September 16, 2024
Discovery of A-910, a Highly Potent and Orally Bioavailable Dual MerTK/Axl-Selective Tyrosine Kinase InhibitorYiyun Yu, Miyeon Jang, Julie Miyashiro, et al.
Nature|September 28, 2017
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumoursLoren M Lasko, Clarissa G Jakob, Rohinton P Edalji, et al.
Nature|May 18, 2018
Author Correction: Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumoursLoren M Lasko, Clarissa G Jakob, Rohinton P Edalji, et al.
Molecular Cell|May 21, 2021
Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibitionSimon J Hogg, Olga Motorna, Leonie A Cluse, et al.
Pageof 13